Exscientia announces expansion of its precision oncology pipeline

Oxford, england--(business wire)--exscientia plc (nasdaq: exai) today announced two new wholly-owned precision oncology development candidates, exs74539 (‘539), an lsd1 inhibitor, and exs73565 ('565), a malt1 protease inhibitor. these compounds have been precision designed to improve the potential for patient benefit and solve complex design issues that may limit the probability of success of other compounds in development.
EXAI Ratings Summary
Quant
EXAI Quant Ranking
Sector
Industry
Quant Rating
Quant Score